Literature DB >> 16919716

HPV DNA testing in cervical cancer screening: from evidence to policies.

Tom Cox1, Jack Cuzick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16919716     DOI： 10.1016/j.ygyno.2006.07.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  9 in total

1.  Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer.

Authors:  S L Sudenga; S Shrestha
Journal:  Int J Infect Dis       Date:  2013-02-27       Impact factor: 3.623

2.  RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus.

Authors:  Paola Cattani; Alessia Siddu; Sara D'Onghia; Simona Marchetti; Rosaria Santangelo; Valerio G Vellone; Gian Franco Zannoni; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

3.  Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix.

Authors:  Paola Cattani; Gian Franco Zannoni; Caterina Ricci; Sara D'Onghia; Ilaria Nausica Trivellizzi; Aldo Di Franco; Valerio G Vellone; Maria Durante; Giovanni Fadda; Giovanni Scambia; Giovanni Capelli; Rosa De Vincenzo
Journal:  J Clin Microbiol       Date:  2009-10-14       Impact factor: 5.948

4.  The impact of human papillomavirus information on perceived risk of cervical cancer.

Authors:  Laura A V Marlow; Jo Waller; Jane Wardle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

5.  mRNA and DNA detection of human papillomaviruses in women of all ages attending two colposcopy clinics.

Authors:  Aris Spathis; Christine Kottaridi; Aikaterini Chranioti; Christos Meristoudis; Charalambos Chrelias; Ioannis G Panayiotides; Evangelos Paraskevaidis; Petros Karakitsos
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

6.  Diagnostic Value of the CareTM HPV Test in Screening for Cervical Intraepithelial Neoplasia Grade 2 or Worse

Authors:  Mojgan Karimi Zarchi; Effat Heydari; Afsarolsadat Tabatabaie; Mansour Moghimi; Wesam Kooti
Journal:  Asian Pac J Cancer Prev       Date:  2017-03-01

7.  The high prevalence of HPV and HPV16 European variants in cervical and anal samples of HIV-seropositive women with normal Pap test results.

Authors:  Lays Paula Bondi Volpini; Neide Aparecida Tosato Boldrini; Luciana Bueno de Freitas; Angelica Espinosa Miranda; Liliana Cruz Spano
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

8.  Sociodemographic predictors of HPV testing and vaccination acceptability: results from a population-representative sample of British women.

Authors:  Laura A V Marlow; Jo Waller; Jane Wardle
Journal:  J Med Screen       Date:  2008       Impact factor: 2.136

9.  Human papillomavirus genotypes distribution among Gabonese women with normal cytology and cervical abnormalities.

Authors:  Samira Zoa Assoumou; Angelique Ndjoyi Mbiguino; Barthelemy Mabika Mabika; Sidonie Nguizi Ogoula; Mohammed El Mzibri; Abdelkrim Khattabi; My Mustapha Ennaji
Journal:  Infect Agent Cancer       Date:  2016-01-15       Impact factor: 2.965
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.